Delayed onset hypophysitis after therapy with daclizumab for multiple sclerosis - A report of two cases.

Daclizumab (DAC), a humanized monoclonal antibody that binds to the interleukin (IL)-2-receptor alpha chain, was approved in May 2016 for treatment of relapsing-remitting multiple sclerosis (RRMS). Approval was suspended in March 2018 after occurrence of severe liver failure and fatal meningoencephalitis in several patients treated with DAC. We report the clinical, laboratory and neuroimaging findings of 2 patients, who developed hypophysitis about 4 months after cessation of therapy with DAC. This report identifies delayed onset hypophysitis as a previously unrecognized severe side effect of DAC, highlighting the importance of continuous pharmacovigilance and patient monitoring even after cessation of DAC therapy. Copyright © 2020 Elsevier B.V. All rights reserved.

Citation

Frauke Stascheit, Linna Li, Knut Mai, Karl Baum, Eberhard Siebert, Klemens Ruprecht. Delayed onset hypophysitis after therapy with daclizumab for multiple sclerosis - A report of two cases. Journal of neuroimmunology. 2021 Feb 15;351:577469

Mesh Tags

Substances

PMID: 33387829

search → result